CRY: Reason for Selling

This post is a companion to the entry in the NFTRH Trade Log where it was noted that the profit was too large to ignore (20%+) and the stock is now sold. The spike upward has been relentless but CRY is now overbought and filling a gap from October. The trade worked like a charm and while I have seller’s remorse, I sold it because I have plenty of other medical device exposure at the moment.

For free website readers, we had been noting this one each week as CRY consolidated its post-earnings spike down to the 50 & 200 day moving averages, as it was a regular feature in the NFTRH+ Charts & Notes segment.


Subscribe to NFTRH Premium for an in-depth weekly market report, interim updates and NFTRH+ chart and trade ideas; or the free eLetter for an introduction to our work. You can also keep up to date with plenty of actionable public content at by using the email form on the right sidebar. Or follow via Twitter @BiiwiiNFTRH, StockTwits or RSS. Also check out the quality market writers at